Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
about
A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.A sensitive and selective liquid chromatography/tandem mass spectrometry method for determination of MLN8237 in human plasma.A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.Aurora-A identifies early recurrence and poor prognosis and promises a potential therapeutic target in triple negative breast cancerDeep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine.A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumorsThe Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.Aurora-A is a novel predictor of poor prognosis in patients with resected lung adenocarcinomaAurora kinase inhibitor patents and agents in clinical testing: an update (2009-10).Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?JAK2 inhibition for the treatment of hematologic and solid malignancies.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.The Aurora kinase inhibitors in cancer research and therapy.Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy.Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.Clinical Development of Anti-mitotic Drugs in Cancer.Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors.Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.Aurora kinase inhibitors: Potential molecular-targeted drugs for gynecologic malignant tumors.Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma.RIPK1-dependent cell death: a novel target of the Aurora kinase inhibitor Tozasertib (VX-680).Mastl overexpression is associated with epithelial to mesenchymal transition and predicts a poor clinical outcome in gastric cancer.A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
P2860
Q33408947-5F752BDF-ADD6-4617-A05D-7DD20A279FF0Q33579079-4E28E983-27C5-4A65-9ED3-C58B40F692F7Q34133201-04B19AFE-9358-4E77-8754-B27E906F1F79Q34448958-5A0F257C-B64A-4672-9B94-C4C80326967DQ34599715-FE6A63B8-58CB-472E-AFB4-0F3C2D1F3319Q35153864-CEE7F452-E9E7-45B6-AF44-56C60748119FQ35289072-A7661DE5-4003-4AE1-820C-FB188A91F9F4Q36133043-A32797C9-F196-41AF-88E0-3E43109F8E8CQ36794006-B66D9F44-9134-4BCE-BA7E-F0978FCA66FCQ37366202-77FEC025-6C6A-4D00-A1F8-F6F672C6657AQ37401839-D734FB9C-1D4A-462D-806F-4B2FE2117F02Q37725402-59A4BC73-5531-4311-A142-A10F199ACA8FQ37876882-3C37A926-5ADE-4DE1-88C8-F533B63027A4Q37994256-06018175-E479-475B-AE69-A2E4CA608D86Q38001733-A5AC7AE3-1549-47B6-AA71-0CCB2F113168Q38099046-AE99B775-BE6B-4BC3-BCA7-34865B17C905Q38221107-553D9EC6-6C07-423E-BF71-45559B722525Q38756932-BC236FFE-78FD-4C28-BB58-0972827C31D5Q38894287-4F43D76E-270B-455B-8044-551BF705E94FQ39194457-BD4B5338-5C65-46FB-9C19-21D1CEA31BA5Q39363642-3A34DB8C-19E5-48C4-A932-2482B1F09D47Q39608458-03A26E10-DC31-43FD-B81B-BCEA3E8FF576Q41463339-8DC614C0-D394-43AF-B4F3-13E2B6A5DFF2Q42562915-7B7E3618-3E0C-427C-A178-1AE1F32AB3D8Q42689215-E8467C54-C833-4B3D-B66B-479E82A6A053Q46501542-AEEBB7A7-27EF-435A-8ACC-C7E79D2B77CDQ49025576-9F3FA14D-1D16-4A26-99BA-D8427A9B5647Q49284340-FCC4B032-23DB-4C51-9FB8-A4B82F2C6110Q52681024-FB77B73F-611B-465E-B631-BA27FDE7A919Q54498929-A70EAFE3-F98F-4490-81F1-C503BC988FC6
P2860
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase I dose escalation study ...... ts with advanced solid tumors.
@ast
Phase I dose escalation study ...... ts with advanced solid tumors.
@en
Phase I dose escalation study ...... ts with advanced solid tumors.
@nl
type
label
Phase I dose escalation study ...... ts with advanced solid tumors.
@ast
Phase I dose escalation study ...... ts with advanced solid tumors.
@en
Phase I dose escalation study ...... ts with advanced solid tumors.
@nl
prefLabel
Phase I dose escalation study ...... ts with advanced solid tumors.
@ast
Phase I dose escalation study ...... ts with advanced solid tumors.
@en
Phase I dose escalation study ...... ts with advanced solid tumors.
@nl
P2093
P2860
P1476
Phase I dose escalation study ...... ts with advanced solid tumors.
@en
P2093
Ann Marie Leighton
Anne M Traynor
Baiteng Zhao
Boyd B Scott
Jason Clark
Maureen Hewitt
Patricia A Watson
Peter J O'Dwyer
Steven J Freedman
P2860
P2888
P304
P356
10.1007/S00280-010-1318-9
P577
2010-04-13T00:00:00Z
P5875
P6179
1015138321